

ISSN 2221-1691(Print) ISSN 2588-9222(Online) CODEN APJTC7

# Asian Pacific Journal of Tropical Biomedicine





jsian Pacific <b>'ropical I</b>	: Journal ( Biomed	of licine	Impact Factor 2021	: 1.514 (@Clarivate An	Sea alytics)	rch Advanced St
cial publication of Editorial Off					Users	Online: 643 🚔 🔀
About	Articles	Authors	Search	Subscribe	Contact U	s Reader Login
ditorial Board						About the journal
Editors-in-Chief					(	SUBMIT ARTICLE
Department of Microbiology, Jniversity, Washington DC, US E-mail: jbethony@gwu.edu	Immunology & Tropic SA	al Medicine, School c	of Medicine and Health	ו Sciences, The George א	Washington	SUBSCRIBE
Prof. Dr. Santiago Mas-Coma Departamento de Parasitologi	a, Facultad de Farmacia	a, Universidad de Valen	cia, Valencia, Spain		(	POPULAR ARTICLES
rof. Dr. Vanessa Steenkamp					(	JOIN AS REVIEWER
epartment of Pharmacology, -mail: vanessa.steenkamp@	University of Pretoria, F up.ac.za	Pretoria, South Africa			(	GET EMAIL ALERTS
Nazni Bte Hj. Wasi Ahmad Senior Research Officer, Medical Entomology Unit, Institute for Medical Research, Kuala Lumpur, Malaysia E-mail: nazni@imr.gov.mv					(	RECOMMEND
resident Executive-Editor-i rof.Cui Bo lainan Medical University Jou -mail: bcui1980@outlook.cor	i <b>n-Chief</b> ırnal Publisher, Hainan I n	Medical University, Haik	ou, China			
e <b>puty Editors-in-Chief</b> rof. Dr. Jong-Yil Chai epartment of Parasitology ar	nd Tropical Medicine, Se	eoul National University	College of Medicine, Se	eoul, Korea		
r. Pierre Roques nmunoVirology Division, Insti	itute for Emerging Disea	ases and Innovative The	erapies, Fontenay-aux-R	Roses, France		
r. Alcides Troncoso epartment of Infectious Dise	ases, School of Medicin	e, Buenos Aires Univer	sity, Buenos Aires, Arge	entina		
or. Stephen Munga Centre for Global Health Rese	arch, Kenya Medical Re	esearch Institute, Nairob	bi, Kenya			
ssociate Editors-in-Chief						
<sup>r</sup> of. Giuseppe La Torre epartment of Public Health a	nd Infectious Diseases,	Sapienza University of	Rome, Rome, Italy			
rof. Odir Antônio Dellagostin iotechnology Unit, Center for	· Technology Developme	ent, Federal University c	of Pelotas, Pelotas, Braz	zil		
rof. Sung-Jong Hong epartment of Medical Enviro	nmental Biology, Chung	-Ang University College	e of Medicine, Seoul, Ko	rea		
rof. Hassan Vatandoost epartment of Entomology ar edical Sciences, Teheran, Ira	nd Vector Control, Scho an	ool of Public Health and	d National Institute of H	łealth Research, Teheran U	Iniversity of	
rof. Maria José Ferreira epartment of Pharmaceutica	I Chemistry, Faculty of F	Pharmacy, University of	Lisbon, Lisbon, Portuga	al		
r. Leonard E. G. Mboera ational Institute for Medical F	Research, Dar es Salaai	m, Tanzania				
rof. Dr. Ivàn Darìo Vélez acultad de Medicina,Universi	idad de Antioquia, Mede	ellìn, Colombia				
ditorial Directors						
ssoc. Prof. Dr. Saravanan Th	nangamani					
epartment of Pathology, Univ	versity of Texas Medical	Branch (UTMB), Galve	ston, USA			
rof. Dr. Laura Bongiovanni aculty of Votorinany Modicing	Liniversity of Terame	Toromo Italy				

Statistic Editors

#### 8/9/22, 10:46 PM

Assoc. Prof. Khaled Khatab Health Economics Modelling and Medical Statistics, Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK

Assist. Prof. Sarath Chandra Janga Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, USA

#### Executive Editors

Prof. Dr. Salah Akkal Department of Chemistry, University of Constantine, Constantine, Algeria

Dr. Hervé Hoste French National Institute for Agricultural Research, Université de Toulouse, Toulouse, France

Prof. Thomas N. Jr. Tully Department Veterinary Clinical Sciences, Louisiana State University School of Veterinary Medicine, Baton Rouge, USA

Prof. Dr. Barbara R Conway Department of Pharmacy, University of Huddersfield, Huddersfield, UK

#### Executive Members of Editorial Board

Assoc. Prof. Vittorio Sambri Unit of Microbiology, Department of Specialistic, Diagnostic and Experimental Medicine, University of Bologna, Bologna, Italy

Prof. Dr. Qiushui He Department of Microbiology and Immunology, University of Turku, Turku, Finland

Assist. Prof. Dr. Bindu Sukumaran Emerging Infectious Diseases Programme, Duke-NUS Medical School, Singapore

Prof. Dr. Suhail Ahmad Department of Microbiology, Kuwait University, Kuwait City, Kuwait

Prof. Indra Vythilingam Department of Parasitology, University of Malaya, Kuala Lumpur, Malaysia

Prof. Dr. Wael Mohamed Abou EL-Makarem EL-Deeb Department of Clinical Studies, College of Veterinary Medicine and Animal Resources, King Faisal University, Al-Ahsa, Saudi Arabia

Assoc. Prof. Dr. Ben Slama Karim Département de Biotechnologie, Université de Tunis El Manar, Tunis, Tunisia

Prof. Bing Huang Department of Animal Parasitology, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Science, Shanghai, China

#### Prof. Xiao-Nong Zhou National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, China

Dr. Nahid Einollahi Department of Lab Medical Sciences, Faculty of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran

#### Prof. Dr. Munir Aktas Department of Parasitology, College of Veterinary Medicine, Firat University, Elazig, Turkey

Dr. José Manuel Lorenzo Rodríguez Researcher in Meat Technology Centre of Galicia, Meat Technology Centre of Galicia, Galicia, Spain

Prof. Dr. Jeong Hwan Shin Department of Laboratory Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

Luis Ignacio González Granado Teaching assistant, Immunodeficiencies Unit , Hospital 12 de Octubre, Madrid, Spain

#### Dr. Abhishek Mathur

Executive Director (R\$D), NCS Group, Nagpur, Maharashtra, India

#### Dr. Ahmed Ismail

Consultant Clinical Pathologist & Chief Lab Services, Supreme Council of Health, Doha, Qatar

Dr. Américo David Rodríguez Ramírez Centro Regional de Investigación en Salud Pública, Chiapas, Mexico

Prof. Xue-Jie Yu Department of Pathology,University of Texas Medical Branch, Texas, USA

#### Prof. Arun Kumar

Department of Biochemistry, Shri Shankaracharya Institute of Medical Sciences, Bhilai, India

Prof. Dr. Chia-Kwung Fan Department of Parasitology, Taipei Medical University College of Medicine, Taipei

Assist. Prof. Dr. Cyrille Bisseye Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, UFR/SVT, Ouagadougou , Burkina Faso

Prof. Dr. Dongmi Kwak College of Veterinary Medicine, Kyungpook National University, Daegu, Korea

Dr. Donovan Anthony McGrowder Chemical Pathology Department, Faculty of Medical Sciences, University Hospital of The West Indies, Kingston, Jamaica

8/	/9/22, 10:46 PM Asian Pacific Journal of Tropical Biomedicine : About u
	Dr. Farouk El Allaki Epidemiology and Surveillance Section, Canadian Food Inspection Agency, Quebec, Canada
	Prof. Dr. Gabriel Trueba Ciencias Biológicas y Ambientales, Universidad San Francisco de Quito, Quito, Ecuador
	Assoc. Prof. Gordana J. Dragovic Lukic Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade, Belgrade, Serbia
	Dr. Hanspeter Marti Swiss Tropical and Public Health Institute, Basel, Switzerland
	Prof. Dr. Herbert Auer Department of Medical Parasitology, Medical University of Vienna, Vienna, Austria
	Hetron Mweemba Munang'andu Department of Basic Sciences and Aquatic Medicine, Norwegian School of Veterinary Science, Oslo, Norway
	Dr. Irma Khachidze Department of Behavior, Cognition Functions and Human Psychophysiology, Beritashvili Institute of Physiology, Tbilisi, Georgia
	Dr. Jean-François Faucher Praticien hospitalier en maladies infectieuses et tropicales, CHU de Besançon, Service des maladies infectieuses et tropicales, Hôpital Minjoz, Besançon cedex, France
	Dr. José A. Oteo Infectious Diseases Department, Center of Rickettsioses and Vector-borne Diseases, Hospital San Pedro-CIBIR, Logroño, Spain
	Dr. Juraj Majtán Section of Molecular and Applied Zoology, Institute of Zoology,Slovak Academy of Sciences, Bratislava, Slovakia
	Dr. Kalman Imre Department of Animal Production and Veterinary Public Health, Faculty of Veterinary Medicine, Banat University of Agricultural Sciences and Veterinary Medicine Timisoara, Timisoara, Romania
	Dr. Kingsley Badu Noguchi Memorial Institute for Medical Research, University of Ghana, College of Health Science, Accra, Ghana
	Lala Ravaomanarivo Département d'Entomologie, de la Facultés des Sciences d'Antananarivo, University of Antananarivo, Antananarivo, Madagascar
	Prof. Dr. Liwang Cui Department of Entomology, The Pennsylvania State University (PSU), Pennsylvania, USA
	Assist. Prof. Dr. Luís R. Silva Laboratory for Process Engineering, Environment, Biotechnology and Energy (LEPABE), Faculty of Engineering (FEUP) University of Porto, Porto, Portugal
	Dr. M. Fawzi Mahomoodally Department of Health Sciences, Faculty of Science, University of Mauritius, Reduit, Mauritius
	Mamadou C Baldé Institut Pasteur de Guinée, Cheikh Anta Diop University, Kindia, Guinée
	Prof. Dr. Milkyas Endale Department of Chemistry, Hawassa University, Hawassa, Ethiopia
	Dr. Mochammad Hatta Molecular Biology and Immunology Laboratory for Infectious Diseases, Department Microbiology, Faculty Medicine Hasanuddin University, Makassar, Indonesia
	Moses Samje Department of Medicine, Faculty of Health Sciences, University of Bamenda, Bambili, Cameroon
	Assist. Prof. Muftah A. M. Shushni Department of Pharmacognosy,University of Tripoli, Tripoli, Libya
	Dr. Muhammad Akram

Department of Eastern Medicine and Surgery, Faculty of Medical and Health Sciences, The University of Poonch, Azad Jammu and Kashmir, Pakistan

Dr. Musso Munyeme Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka, Zambia

Prof. Dr. Nguyen Hoang Loc Department of Biotechnology, College of Sciences, Hue University, Hue, Vietnam

Dr. Prof. Obembe Olawole Department of Biological Sciences, Covenant University, Ota, Nigeria

Prof. Dr. Pius Tshimankinda Mpiana Department of Chemistry, Faculty of science, University of Kinshasa, Kinshasa, Democratic Republic of the Congo

Prof. Dr. Polrat Wilairatana Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Dr. Pravin Malla Shrestha Energy Biosciences Institute, University of California, Berkeley, USA

#### 8/9

9/22, 10:46 PM	Asian Pacific Journal of Tropical Biomedicine : About us
Dr. Rebuma Firdessa Institute for Molecular Infection Biology, Univ	ersity of Wuerzburg, Wuerzburg, Germany
Prof. Rinaldo Poncio Mendes Faculdade de Medicina de Botucatu, Univers	sidade Estadual Paulista Júlio de Mesquita Filho, Botucatu, Brazil
Dr. Robin A J Nicholas Mycoplasma Group, Department of Statutory	/ and Exotic Bacteria, Veterinary Laboratories Agency (Weybridge), Surrey, United Kingdom
Dr. Assoc. Prof. Samath D Dharmaratne Faculty of Medicine, University of Peradeniya	a, Peradeniya , Sri Lanka
Dr. Assist. Prof. Song Gao Department of Pharmacological and Pharma	ceutical Sciences, The University of Houston, Houston, USA
Dr. Assist. Prof. Tarig Mohamed Saad Alnou Department of Microbiology, Alzaiem Alazha	r ri University, Khartoum, Sudan
Dr. Tashi Tobgay Vector-Borne Disease Control Programme, N	vlinistry of Health Royal Government of Bhutan, Thimphu, Bhutan
Dr. Thomas Dorlo Department of Pharmaceutical Biosciences,	Uppsala University, Uppsala, Sweden
Prof. Tohru Gonoi Medical Mycology Research Center, Chiba L	Jniversity, Chiba, Japan
Dr. Vania Giacomet Department of Paediatrics, University of Mila	n, Luigi Sacco Hospital, Milano ,Italy
Dr. Veasna Duong Virology Unit, Insitut Pasteur du Cambodge,	Phnom Penh, Cambodia
Assist. Prof. Dr. Weaam N. E. Ebrahim Department of Pharmacognosy and Medicina	al Plants, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Dr. Xuanming Shi Department of Physiology, University of Texa	as Southwestern Medical Center, Dallas, TX, USA
Assist. Prof. Dr. Yong Song Faculty of Medicine, Dentistry and Health Sc	iences, The University of Western Australia, Perth, Australia
Dr. Yu Pang National Center for Tuberculosis Control and Chinese Center for Disease Control and Pre	l Prevention, vention, Beijing, China
Assist. Prof. Yuki Eshita Research Center for Zoonosis Control, Hokl	kaido University, Hokkaido, Japan
Dr. Bartholomew N. Ondigo	
Department of Biochemistry and Molecular I	Biology, Egerton University, Nakuru, Kenya

© Asian Pacific Journal of Tropical Biomedicine | Published by Wolters Kluwer - Medknow

Sitemap | What's New | Feedback | Disclaimer | Privacy Notice | FAQ Online since 13<sup>th</sup> December 2017

Editorial and Ethics Policies (cc) BY-NG-SR Open Access S No Fee View mobile site ISSN: Print -2221-1691, Online - 2588-9222



Editorial and Ethics Policies

SN: Print-2221-1691, Online - 2588-9222



**Review Article** 

**Asian Pacific Journal of Tropical Biomedicine** 

journal homepage: www.apjtb.org



### doi: 10.4103/2221-1691.350176

Impact Factor: 1.51

Anticancer drug screening of natural products: *In vitro* cytotoxicity assays, techniques, and challenges

Agustina Setiawati<sup>⊠</sup>, Damiana Sapta Candrasari, F.D. Erika Setyajati, Vincentia Krisnina Prasetyo, Dewi Setyaningsih, Yustina Sri Hartini

Faculty of Pharmacy, Sanata Dharma University, Paingan, Maguwoharjo, Depok, Sleman, Yogyakarta 55282, Indonesia

#### ABSTRACT

Natural products include several diverse compounds that have been found to be effective against cancer. Discovering anticancer compounds in nature is a multistep and complex process that requires pre-clinical and clinical studies. Only a few of the available natural products are used to treat cancer since most of them have very high complexity and low bioavailability. Therefore, the process of anticancer drug discovery requires a straightforward and effective method to assess anticancer activity using *in vitro* assays. This review summarizes various cell-based assays and techniques used to measure cell viability, migration, and apoptosis, focusing in particular on the principles, mechanisms, advantages, and disadvantages of each assay to provide a preliminary platform for cancer drug discovery.

**KEYWORDS:** Drug discovery; Cancer; Natural products; Screening; *In vitro* assay; Cytotoxicity; Migration; Apoptosis

#### **1. Introduction**

Cancer chemotherapy has been used since the mid-20th century[1]. Although over 200 anticancer biopharmaceuticals have been approved, with many more in preclinical or clinical trials, tumor therapies are still emerging[2]. Natural products have been widely studied for their anticancer activities for more than 50 years. For example, vinblastine and vincristine were isolated from active compounds of the Madagascar periwinkle *Catharanthus roseus* G. Don. (Apocynaceae). Other drugs isolated from plants include etoposide, paclitaxel, topotecan, and irinotecan[3–5]. Chemical compounds found in natural products induce canonical processes such as apoptosis and non-canonical cell death mechanisms such as ferroptosis, pyroptosis, and necroptosis[6]. Approximately 600

natural products and dietary substances exhibit *in vitro* anticancer activity against various forms of cancer, such as breast, leukemia, lymphoma, prostate, liver, lung, and myeloma[7]. Such findings have driven attempts to screen natural products as chemopreventive agents.

Anticancer drug discovery is a long complex process involving the screening of new entities, assessment of anticancer activity, production and formulation, *in vivo* toxicity testing in animals, and pre-clinical trials and has unpredictable results<sup>[8]</sup>. The discovery of chemical compounds from natural products that are suitable for use as anticancer drugs has several limitations, including low yield and regulations on plant extraction, implemented in various countries<sup>[9]</sup>. Moreover, only a small fraction of cytotoxic natural products are effective in clinical applications. Therefore, anticancer drug discovery from natural products requires a straightforward and effective method to assess anticancer activity. Additionally, the biodiversity of natural products suggests great potential for the discovery of novel natural anticancer agents.

Despite enhancements in molecular targeting in pre-clinical drug development, testing new molecules requires cytotoxic assays to quickly assess a particular chemical compound[10]. Thus, the need for improved *in vitro* assays to evaluate and predict cytotoxic effects is increasing in anticancer drug discovery. Furthermore, investigating

For reprints contact: reprints@medknow.com

©2022 Asian Pacific Journal of Tropical Biomedicine Produced by Wolters Kluwer-Medknow.

 $<sup>^{\</sup>bowtie}$  To whom correspondence may be addressed. E-mail: nina@usd.ac.id

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Setiawati A, Candrasari DS, Setyajati FDE, Prasetyo VK, Setyaningsih D, Hartini YS. Anticancer drug screening of natural products: *In vitro* cytotoxicity assays, techniques, and challenges. Asian Pac J Trop Biomed 2022; 12(7): 279-289.

Article history: Received 29 May 2022; Revision 8 June 2022; Accepted 29 June 2022 Available online 20 July 2022

apoptosis in cancer cells is critical to evaluating cytotoxic activity. The efficacy of anticancer agents is assessed by their ability to differentiate between cancerous and non-cancerous cells and selectively promote apoptosis<sup>[11]</sup>.

Selecting the most suitable drug screening assay is crucial to minimizing the failure rate in drug discovery. This review highlights *in vitro* anticancer assays used for natural products during the new drug discovery. Diverse methods are reviewed in detail and their advantages and disadvantages are considered.

#### 2. Progress in anticancer drug screening

Anticancer drug screening aims to identify natural metabolites that exhibit antitumor activity. Selected compounds are usually toxic, and their anticancer activity is assessed in humans during the clinical phase[8]. In pre-clinical trials, various platforms can be designed using *in vitro* and *in vivo* testing. However, the ideal platform should be fast, simple, inexpensive, and with predictable pharmacodynamic activity. Between 1955 and 1975, *in vivo* tests approved by the National Cancer Institute Developmental Therapeutics Program were the method of choice for anticancer drug screening.

Before the 1950s, transplantable mouse tumors were utilized to prescreen anticancer drugs, followed by human xenografts to better predict anticancer activity[12]. In the early 1990s, this prescreening assay was replaced by the human *in vitro* cell models using 60 different types of human cell lines that screened up to 20 000 compounds per year for anticancer activity. Furthermore, anticancer drug testing is an arduous and expensive process, requiring up to 15-20 years and costing approximately US\$ 900 million to test 5000 compounds during the initial screening steps, with only one or two compounds eventually being clinically approved[13,14].

Several natural products from plants and antimicrobial fermentation have resulted in the discovery of effective anticancer agents. Vincristine, vinblastine, and vindesine are vinca alkaloids with potent anticancer activity<sup>[5]</sup>. Other compounds derived from microbial fermentation include actinomycin D, doxorubicin, mitomycin C, and bleomycin[15]. Some of the recent advances in anticancer drug discovery include the use of chemical compound library synthesis and high-throughput screening (HTS), which can simultaneously screen many compounds[16]. However, discovering chemicals from natural sources has several drawbacks during the isolation and separation procedures, such as low product yield and regulations regarding plant extractions implemented by different countries[9]. Drug repurposing is another promising strategy for administering marketed therapeutic drugs used for other ailments to treat cancers. For example, in our previous study, the anti-inflammatory drug celecoxib showed cytotoxicity against HeLa cervical cancer cells by inhibiting p53, a tumor suppressor gene[17]. However, most synthetic compounds have unpredictable results<sup>[16]</sup>. Therefore, finding new anticancer entities from natural products is receiving great attention in countries such as Indonesia, which has high plant biodiversity.

The success of anticancer drug development is dependent on the close integration of three major components: targeting, treatment, and technology. Thus, anticancer drug discovery and development have shifted from cytotoxic chemotherapy to personalized medicine, in which molecular-targeted therapy is exploited[18]. Researchers are now focusing on platforms for cancer treatment that involve specific targets of cancer cells. Targeted treatment deploys multiple molecular mechanisms, including proliferation inhibition, immune regulation, apoptosis induction, metastasis suppression, and multidrug resistance reversal[19]. One example of modern molecular-targeted therapy is trastuzumab which treats human epithelial receptor (HER2)-overexpressing breast cancer[20]. Estrogen receptors and HER2 are the most effective breast cancer therapies to date[21].

Despite improvements in molecular targeting in pre-clinical drug development, the testing of new molecules requires cytotoxic assays to quickly assess the chemical compounds under investigation[10]. Thus, improved *in vitro* assays are required to evaluate and predict cytotoxic effects during anticancer drug discovery. Furthermore, the investigation of apoptosis in cancer cells is an effective way to evaluate the cytotoxic activity of chemical and natural compounds. The efficacy of anticancer agents is determined by their ability to differentiate between cancer and non-cancer cells and selectively promote apoptosis[11].

#### 3. In vitro cytotoxic assays

Several methods have been established to measure cytotoxic activity and calculate the number of viable cells during anticancer drug screening<sup>[22]</sup>. Cell viability is defined as the proportion of healthy cells within a population. In general, cell viability assays are employed to measure the response of cells to toxic agents and are widely used for drug screening. Various markers have been used to measure metabolically active cells, such as enzyme activity, cell membrane permeability, cell adherence, adenosine triphosphate production, co-enzyme production, and nucleotide uptake activity<sup>[22]</sup>. Here, we discuss seven *in vitro* cytotoxic assays: cellular enzyme- and protein-based assays, electric cell-substrate impedance sensing, cell-based assays dependent on DNA synthesis, dye exclusion assays, colony formation assays, real-time cell proliferation monitoring, and live-cell imaging.

#### 3.1. Dye exclusion assay

Dye exclusion assays exploit the permeability of the cytoplasmic membrane to measure the number of viable cells<sup>[23]</sup> by applying

various dyes, such as trypan blue, eosin, Congo red, and erythrosine B, to cell culture. Viable cells can prevent the passage of these molecules through the membrane owing to their high selectivity, whereas dead cells cannot[24]. Trypan blue has become one of the most feasible methods for measuring cell viability. With concentrations ranging from 0.04%-0.4%, this inexpensive and efficient dye is especially useful for monolayer cell culture models[25]. Trypan blue is a negatively charged molecule that enters dead cells through their damaged membrane, thereby turning them blue. Meanwhile, living cells exclude the dye, thus appearing clear under a light microscope[22,26]. Eosin Y and Congo red are also effective dyes for visualizing cells under a light microscope; Eosin Y selectively stains the cytoplasm, collagen, and muscle fibers, whereas Congo red stains the cytoplasm[27,28].

#### 3.2. Colorimetric assays

One of the hallmarks of cancer is uncontrolled cell proliferation, which augments the number of viable cells in a system. Cell-based proliferative assays are based on cellular enzyme activity, DNA synthesis, membrane integrity, and adenosine triphosphate levels, which are indicators of both viable and dead cells<sup>[29]</sup>. Several colorimetric and fluorometric assays have been developed for cancer drug screening. These methods are based on the measurement of biochemical markers to determine cellular metabolic activity. A substrate undergoes a measurable color change by an intracellular enzyme in living cells, such that the number of colored cells is proportional to that of viable cells. Applying colorimetric assays to natural products is challenging since some extracts or fractions are inherently colorful, thereby limiting assessment of their efficacy under visible light.

The  $3 \square (4,5 \square$  dimethylthiazol  $\square 2 \square$ yl-)2,5  $\square$  diphenyltetrazolium bromide (MTT) assay is a widely used colorimetric assay for initial drug discovery. MTT can pass through the cell membrane owing to its lipophilic side groups and net positive charge. The tetrazolium salt is then reduced to an insoluble formazan complex by the nicotinamide adenine dinucleotide (NADH) dehydrogenase enzyme, which is present in the mitochondria of viable cells at 37  $^{\circ}$ C (Figure 1A). The solubilizing agents sodium dodecyl sulfate, acidified isopropanol, dimethyl sulfoxide, and dimethylformamide dissolve the formazan complex and are then quantitatively measured at 570 nm using a spectrophotometer[24]. Solubilization of the formazan complex is considered a time-consuming step and requires modification. Dead cells lose their ability to convert MTT to formazan products; therefore, the intensity of color change is directly proportional to the viable cell number in the culture[30]. In some cases, cell lysis is crucial for dissolving formazan because crystals are formed intracellularly. However, the mechanism underlying the solid formazan crystal dissolution remains unclear.

To overcome the time-consuming process of dissolving the



**Figure 1.** (A) Conversion reaction of 3 (4,5 dimethylthiazol 2 yl-)2,5 diphenyltetrazolium bromide (MTT) to formazan. (B) Conversion of 2-(2-methoxy-4nitrophenyl)-3-(4-nitrophenyl)-5- (2,4-disulfophenyl)-2H-tetrazolium (WST-8) to the formazan salt. (C) Conversion of resazurin to resorufin. (D) Reduction of lactate to pyruvate. (E) Luciferin oxidation to oxyluciferin. ATP: adenosine 5'-triphosphate; AMP: adenosine monophosphate. The structures are drawn using MarvinSketch.

formazan complex, water-soluble tetrazolium (WST) assays have been developed, the most common one being the WST-8 assay [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4disulfophenyl)-2H-tetrazolium]. WST-8 was first used by Tominaga in 1999 as a second-generation tetrazolium salt. This salt has high solubility due to the negatively charged sulfone groups on the phenyl rings, which compensate for the positive charge of the tetrazolium ring (Figure 1B)[31]. This negatively charged dye cannot permeate cells and is extracellularly reduced to tetrazolium[30]. The number of viable cells is proportional to the amount of reduced WSTtetrazolium, quantified by measuring absorption at 450 nm[30], thus allowing real-time assays to be performed[32].

Another type of dye, resazurin, which was discovered by Weselsky, is non-fluorescent and converted to resorufin by NADH, nicotinamide adenine dinucleotide phosphate (NADPH), or flavin adenine dinucleotide (FADH)-dependent oxidoreductase enzymes in viable cells[30]. In the late 1920s, cell metabolic activity was used to measure bacterial contamination. Since then, redox dyes have been used to determine the active metabolism of cells for various applications. Resazurin is a physiological buffer-soluble compound with deep blue color in a solution that allows its direct application in cell culture[33]. Once resazurin diffuses through the cell membrane, it is converted to resorufin, which emits a pink color (Figure 1C). When excited at 579 nm, resorufin has an emission wavelength of 584 nm[24].

Lastly, the lactate dehydrogenase (LDH) assay quantifies viable cells based on LDH activity interconverting pyruvate to lactate, accompanied by the oxidation of NADH to NAD<sup>+</sup> in the medium (Figure 1D)[29,34]. In various human tissues, five isoforms of LDH are present in different quantities and with different specificities and kinetics[34]. Cell numbers can be quantified by releasing LDH through cell lysis and measuring the absorbance values at 490 nm, which represents all LDH activity[34]. Thus, modification of the LDH assay can determine the percentage of cell death and inhibition in a single experiment[35].

#### 3.3. Adenosine 5'-triphosphate (ATP) assay

ATP is a principal molecule of energy storage in living cells and is synthesized in the mitochondria. ATP is transported intracellularly and supplies energy for biochemical processes in cells. Since it is an indicator of living cells, measuring the total cellular ATP enables determination of cell viability and cytotoxicity[22]. During cell death, ATP synthesis is halted, and the remaining ATP is degraded by ATPase as the cells lose their membrane integrity[24]. The ATP assay, also called the luciferase assay, is based on the oxidation reaction of luciferin with cellular ATP, catalyzed by added natural firefly luciferase (Figure 1E). The reaction produces light proportional to The luminescence signal is relatively stable and can be measured within a few hours. Overall, the assay is sensitive and can measure a signal when there are more than 50 cells that exist. Moreover, ATP assay can predict the sensitivity of platinum-resistant epithelial ovarian cancer to anticancer agents<sup>[36]</sup>. However, it cannot

distinguish ATP depletion due to the cytotoxic or cytostatic effects of

the drugs, or changes in the cell number or metabolic activities[37].

the number of viable cells and can be measured using a luminometer.

#### 3.4. Colony formation assay (clonogenic assay)

The colony-forming assay, also known as the clonogenic assay, is an *in vitro* assay based on the ability of a single cell to form a colony of at least 50 cells[38,39]. This assay is recognized as the gold standard for ionizing radiation therapy in cellular systems since it was first introduced by Puck and Marcus in 1956[39]. Despite this reputation, colony-forming assay is a time-consuming method that measures the number of colonies through manual counting under a light microscope[38]. This assay can detect the cytotoxic effect of any agent, regardless of its mechanism, if it affects the cell's ability to produce a lineage or kills reproductive cells as a result of chromosome damage and apoptosis. Although many different assays can detect various processes that affect cell numbers, such as proliferation[40], apoptosis[41], and senescence[42], colony-forming assay can only measure the ability of cancer cells to form colonies after treatment.

#### 3.5. Electric cell-substrate impedance sensing

Electric cell-substrate impedance sensing is used to study real-time cell attachment, growth, morphology, function, and motility on a solid substrate[43,44]. This technique investigates the invasiveness of cancer cells, barrier function of endothelial cells, cell-cell and cellextracellular matrix (ECM) interactions, signaling pathways for drug discovery, and wound-healing processes[44,45]. Impedance increases during the adherence and spread of cells over the electrodes (Figure 2)[46]. However, it decreases during wound healing and cell death. In electric cell-substrate impedance sensing experiments, cells are directly seeded in a confluent state on integrated gold-film electrodes. The proximity of the cell layer to the thin gold electrodes results in extremely sensitive measurements. However, there is no basolateral fluid compartment owing to cell adherence to the electrode[45]. In a previous study, the electrode was designed as a microelectrode array consisting of many uniform single microelectrodes on a shared platform. Every microelectrode could target heterogeneous cell properties instead of providing collective cell responses with fluctuating signals<sup>[47]</sup>. Therefore, repetition of the set measurements and proper fitting methods for the obtained average data are required.



Figure 2. The current pathway in adherence cells at high frequency in electric cell-substrate impedance sensing (>40 kHz), modified from Benson et al[46].

#### 4. Cell migration and invasion assay

In biology, migration is a process in which a cell moves within tissues or between different organs. Thus, invasion is defined as the cellular penetration of tissue barriers by passing through the basement membrane and infiltrating the interstitial tissue[44]. In experimental cell biology, however, migration is defined as the movement of cells on two-dimensional (2D) surfaces without any obstruction. On the contrary, invasion is defined as cell movement in a three-dimensional (3D) matrix because the cell reciprocally modifies its shape and interacts with the ECM[44,48]. Cell migration can regulate normal physiological processes, particularly embryonic and branching morphogenesis, nervous system development[49], gastrulation[50], vascular development[51], wound healing, and immune-cell movement[52]. However, unregulated cell migration might contribute to many pathological phenomena, such as inflammation and cancer metastasis[53]. Cancer cells spread from the primary tumor mass through the blood and lymphatic systems by crossing the basement membranes and endothelial walls to colonize distant organs[53,54]. Hence, understanding cellular migration and invasion is important for fighting cancer. Numerous studies on cancer drug discovery have investigated the role of migration and invasion when studying the effects of novel therapeutic compounds on metastasis progression[55]. In this section, we review in vitro assays that are suitable for HTS and less expensive than in vivo assays.

#### 4.1. Scratch assay

The *in vitro* scratch assay is an easy, simple, and economical method for measuring cell migration<sup>[56]</sup>. The first step is to create a scratch or wound on a 2D monolayer cell culture with a tip or insert; then images are captured, and the gap is measured at the beginning and end of specific interval times<sup>[55,56]</sup>. Cell movement can be calculated from the residual gap between scratched cells, shown as the percentage of wound closure at different time points<sup>[57]</sup>. The timescale is usually no longer than 24 h to avoid taking into account the effects of cell proliferation and changes in cell survival. Limitations of this assay include the possibility of uneven gaps in the scratch, scratched cells reattaching to the gap area, and the surface

of the polystyrene plate being accidentally scraped off[58]. To solve these issues, cells are seeded directly onto cell culture inserts without wounding or scratching the monolayer culture[55,59]. This assay is employed to assess the effects of both soluble compounds and solid materials on cell migration[57].

#### 4.2. Live imaging

Live imaging has been used to track cancer cells to understand the mechanism by which their highly dynamic migratory cell motility is affected by physical, chemical, and molecular aspects[60]. Individual cells are tracked to analyze their collective dynamics and the mechanism by which they contribute to cancer metastasis. Cells are labeled either *ex vivo* or *in vivo* and then individually tracked using optical imaging. The *ex vivo* labeling includes radioactive, paramagnetic, or fluorescent tracers, whereas *in vivo* labeling uses radioactive, fluorescent, or luminescent imaging[61]. The direction and distribution of cell migration are plotted in an angular histogram, later referred to as the rose diagram. A previous study showed that untreated cancer cells moved more randomly than treated cells (Figure 3)[62].

#### 4.3. Transwell assay

One way of determining the effectiveness of anticancer drugs is by investigating their influence on cell migration and invasion. The Transwell assay employs a chamber known as the Boyden Chamber, which is separated into two compartments using a filter pore membrane 3-12 µm in diameter, through which cells migrate[44,63]. The inserted membrane is coated with a collagen I -containing ECM to mimic biological conditions. One limitation of this assay is the high cost of ECM-coated membranes, which was considered in a previous study that developed a paper scaffold to replace the culture platform[44]. Cells are cultured in the upper chamber and can migrate through the membrane pores into the lower chamber, which contains higher serum concentrations or attractants. The cells that have migrated are fixed and stained with a cytological dye (hematoxylin, toluidine blue, or crystal violet) and then quantified. Another method counts migrated cells by dissociating them from the membrane and staining them with a fluorescent dye[64].



Figure 3. The direction and movement of untreated and treated cancer cells.

#### 5. Apoptosis assay

The word "apoptosis" is derived from Greek and means "falling off," which references the falling leaves in autumn. It describes the condition under which cells pursue regulated cell death after receiving certain stimuli[65]. Cells undergoing apoptosis exhibit cytoplasmic shrinkage, chromatin condensation, nuclear fragmentation, membrane blebbing, and the formation of apparently intact apoptotic bodies that are efficiently phagocytosed by surrounding cells and degraded within lysosomes[65]. Apoptosis is orchestrated and regulated by cellular processes under physiological and pathological conditions[66]. Cancer involves the transformation of a normal cell into a malignant cell while avoiding any type of cell death, particularly apoptosis[67]. Impairment of apoptotic pathways is critical in carcinogenesis, and many novel therapies targeting apoptosis are feasible for application in cancer treatment[66]. Measurement of apoptosis is a critical evaluation of the cytotoxic activity of chemical or natural compounds. Since cancer therapy aims to induce cell death without extensive damage to normal cells, studies that focus on the genes involved in apoptotic signaling have played an important role in oncology research[11].

Thus, the development of apoptosis assays in cancer studies has enhanced the discovery of cancer drugs from natural products. The efficacy of anticancer agents is determined by their ability to differentiate between cancerous and non-cancerous cells and selectively promote apoptosis[11]. Various methods that measure morphological and biomolecular processes, such as DNA content and fragmentation, loss of membrane integrity, and other morphological cell features are used to detect apoptosis[68]. Apoptosis assays are the most commonly used method to investigate the anticancer activity of compounds from natural products.

#### 5.1. Double-staining method

In the double-staining method, two fluorescent dyes are applied to cells (acridine orange and ethidium bromide) to identify apoptosisassociated membrane changes, which are then observed under a fluorescence microscope[11]. This protocol can also accurately distinguish between cells at different stages of apoptosis. Acridine orange enters the cells, intercalates into the DNA of normal and early apoptotic cells, and produces a green fluorescent color. In contrast, ethidium bromide can only penetrate late apoptotic and dead cells through the damaged membrane and bind to DNA fragments or apoptotic bodies to emit an orange-red fluorescence[69].

#### 5.2. Comet assay

The comet assay is a simple, rapid, and sensitive tool that measures DNA damage in eukaryotic cells. This assay, also known as single-cell gel electrophoresis and microgel electrophoresis, uses a microelectrophoresis technique for direct visualization of DNA damage in individual cells<sup>[70]</sup>. Östling and Johanson introduced this assay in 1984 to observe the effect of irradiation on cells. The cells are lysed, and an electric current is applied to pull the DNA from the nucleus. The DNA is then stained with a fluorescent dye, and the damaged DNA is revealed. The name of this assay is derived from the comet-like appearance of the fragmented DNA<sup>[70,71]</sup>.

#### 5.3. TUNEL assay

Apoptosis is often detected by identifying DNA breakage. DNA fragments of 180-200 bp in size can be separated into a ladderlike line by agarose gel electrophoresis. However, this assay cannot identify the source of fragmented DNA at the single-cell level in a mixed-cell population[72]. TUNEL stands for terminal deoxynucleotidyl transferase dUTP nick end labeling and is a method to detect the blunt 3' hydroxyl ends of double-stranded DNA breaks using terminal deoxynucleotidyl transferase (TdT)[73,74]. This enzyme catalyzes the labeled attachment of deoxyuridine triphosphates (dUTPs) to DNA termini breaks, which are further detected using immunoperoxidase techniques.

This assay is relatively simple and easy to perform, and TUNEL assay kits for single-cell analysis in cell cultures and tissue samples are widely available. The TUNEL assay is a reliable method for detecting apoptosis in a histochemical model for tissues and adherent and suspension cell lines. The sensitivity of this assay is due to the use of specific markers, such as bromodeoxyuridine labeling (BrdU), fluorescein labeling, thymidine analogs, and 5'-ethynyl2-deoxyuridine labeling (EdU)[73]. DNA breakage is not a unique feature of apoptosis and also exists in necrosis[75,76]. Therefore, the accuracy of the TUNEL assay in detecting apoptosis, in particular, has been examined in several studies.

#### 5.4. Flow cytometry

Flow cytometry is the most common method for identifying dead cells, revealing the mode (apoptosis or necrosis) as well as the mechanism of cell death[77]. Hallmarks of apoptosis include membrane blebbing, nucleus fragmentation, decreased cellular

volume, and the formation of apoptotic bodies. In contrast, the morphological features of necrosis are early plasma membrane rupture, rapid cytoplasmic, nuclear swelling, and organelle breakdown, which induce immune responses[78,79]. Although apoptosis and necrosis have distinct morphological features, distinguishing between these processes is difficult[80].

Flow cytometry measures changes in cell morphology and chromatin condensation using laser light beam scattering[77]. Annexin V/propidium iodide (PI) staining enables distinction between apoptosis and necroptosis at the single-cell level. Annexin V is a polypeptide that binds to phospholipids and phosphatidylserine but cannot enter the cell. At an early apoptotic stage, cells stain annexin V positive and PI negative, due to their intact membrane preventing PI staining. In contrast, membrane damage occurs at a late apoptotic or early necroptotic stage, which enables the PI membraneimpermeable dye to bind directly to DNA[80]. To distinguish cellular phenotypes precisely, such as proliferation, division, necrosis, and apoptosis (Figure 4A & 4B), imaging flow cytometry has been developed to combine the strengths of microscopy and flow cytometry, which enables the high-throughput characterization of cells in populations on a more precise microscopic scale[41].

## 6. Challenges and insights of anticancer drug screening of natural products

Current methods are insufficient for the effective *in vitro* HTS of small molecules and characterization of the molecular metastatic cascade complex. Most studies on cell migration are limited to endpoint assays. New *in vitro* time-lapse microscopy approaches, complex metrics analysis, and the downstream interpretation of motility findings are daunting but essential challenges for researchers in this field.

#### 6.1. Escaping the apoptosis mechanism

Numerous plant-derived compounds such as quercetin, resveratrol,

lycopene, kaempferol, curcumin, epigallocatechin gallate, and capsaicin can kill cancer cells by triggering apoptosis via inhibiting several important pathways, including the death receptor apoptotic pathway (extrinsic apoptosis pathway), mitochondrial pathway (intrinsic apoptotic pathway), NF-KB signaling pathway, MAPK signaling pathway, and PI3K-Akt pathway[81,82]. However, solid tumor-derived cell lines under treatment can recover from apoptosis during a process called "anastasis," from the Greek word meaning "resurrection"[73]. Tumor-derived cell lines are used to identify outliers that appear as "dead cells" under conventional pre-clinical assays. These outliers remain viable and active, secrete growth factors, resist chemotherapy, and proliferate actively. Although some natural products might induce non-canonical cell death, such as ferroptosis, cancer cells can be killed by radicals or oxidants induced by drugs[6]. Therefore, using natural products as chemopreventive agents remains a promising strategy.

#### 6.2. Compound complexity of natural products

Natural product-based chemical compounds are a cocktail of substances capable of targeting multiple cancer signaling pathways and serve as a vigorous form of cancer therapy by increasing effectiveness, preventing drug resistance, and decreasing the necessary dose to achieve responses[83]. Additionally, natural products are typically low in cost and have few side effects, making them attractive as cancer treatments. Many natural products have multiple cancerous cell targets. For instance, curcumin[84,85], astragaloside IV[86], and emodin[87,88] can induce apoptosis in cancer cells and modulate the immune response to tumor formation. Additionally, paclitaxel, one of the most common naturally derived chemotherapeutic-targeting microtubules, also successfully inhibits angiogenesis by suppressing vascular endothelial growth factors at low concentrations[89].

However, having multiple targets comes at a price, and natural products might have low efficacy at low concentrations, necessitating anticancer drug discovery based on HTS. Complex mixtures of compounds, including phenolic compounds and plant

**Figure 4.** Schematic illustration of the staining strategy in flow cytometry. (A) Identification of healthy cancer cells (double-negative), early and late apoptosis (annexin V-positive and double-positive, respectively), and necrotic (double-positive) cell populations. (B) Gating illustration of the cells in flow cytometry. Adapted from Pietkiewicz *et al*[80].



tannins, function as protein binders, which might give false-positive results in HTS. Therefore, crude plant extracts cannot be used[9]. However, detanninization might reverse this problem by removing the interfering tannins. Despite the potential of natural products in anticancer therapy, most are considered immature candidates for drug therapy, and interest in natural products in anticancer drug discovery is declining[90]. Hence, a novel strategy is to utilize natural products in medicinal chemistry. In identifying lead compounds, bioactivity-directed fractionation can be applied in anticancer drug discovery. A refined approach involves pre-fractionating a crude extract into an almost pure compound for HTS[13]. As discovery methods for treatments develop, the interest in natural product research has been guided towards molecular-targeted compounds. To date, small-molecule targeted compounds have shown distinct selectivity in every type of cancer cell. Thus, their small size (molecular weight less than 1000) allows them to bind to multiple intracellular and extracellular targets by oral administration[91,92].

## 6.3. Bioavailability issues of compounds derived from natural products

While the use of natural products lowers the cost of cancer care, their clinical use is limited due to their low solubility, rapid metabolism, and poor bioavailability[93]. Although natural products have significant effects *in vitro* using cell cultures, as well as *in vivo* in animal models, their clinical efficacy is low[94]. For instance, genistein inhibits breast and prostate cancer cells by regulating vital genes involved in cell proliferation, apoptosis, the cell cycle, oncogenesis, and signaling pathways[95]. However, the clinical trial did not reveal breast cancer inhibition in healthy high-risk Western women, suggesting its low efficacy is poor bioavailability due to extensive phase II metabolism *via* glucuronidation and sulfonation in the intestine and liver[97].

Curcumin is a well-known chemopreventive compound found in turmeric species and exhibits numerous *in vitro* and *in vivo* anticancer activities in various types of cancer[82]. However, studies in humans have revealed poor bioavailability, even at high doses (12 g/day). The low curcumin plasma level is a consequence of poor absorption, low aqueous solubility, and extensive metabolism, resulting in its rapid elimination from the human body[98]. Although curcumin is considered safe to consume and pharmacologically active against cancer, its pharmacokinetic properties revealed poor bioavailability after oral administration in human studies. One study suggested that 1.0 g/kg of curcumin provided 0.13 g/mL in the plasma after 15 min, reaching a maximum of 0.22  $\mu$ g/mL after 1 h, followed by a rapid decline to below the limit of detection within 6 h[98]. Therefore, designing a curcumin delivery system with good bioavailability is a promising strategy for cancer chemoprevention. Another strategy to improve natural product bioavailability is to use nanotechnology. Unfortunately, drug nano-formulations can raise toxicity levels and are often rapidly eliminated by the mononuclear phagocytic system[93]. Currently, exosome delivery is considered a novel strategy for improving the pharmacokinetics of natural products. Exosomes are extracellular vesicles with 30-150 nm in diameter secreted by various types of cells, including cancer cells. They have a high drug-carrying capacity that is non-immunogenic and have a low-toxicity profile. Exosomes extend drug circulation in the blood, reducing the elimination rate and protecting drugs from degradation. Thus, application of this exosome and the functional and safety properties of exosome delivery should be elucidated[99].

#### 7. Conclusion and prospects

Natural products are promising sources of biologically active compounds that could be used against cancer cells. The discovery of new natural product-based anticancer entities with a high degree of biodiversity is still receiving enormous attention in Indonesia. To enhance new anticancer drug discoveries, cell-based in vitro assays and techniques have been well developed. Cytotoxic assays based on cellular metabolic activity and cell migration assays are still popular for screening anticancer agents from natural products. Furthermore, apoptosis has been extensively studied to investigate the response to chemotherapy and to improve therapeutic outcomes as a goal of translational and personalized medicine. However, screening anticancer compounds from natural products has limitations, such as their ability to escape from the apoptosis mechanism, their natural compound complexity, and poor bioavailability. Therefore, only a few pure compounds from cytotoxic natural products demonstrate effects in clinical cancer therapy. Thus, the goal of anticancer drug screening of natural products is to overcome these limitations by designing effective drug delivery methods and focusing on bioassayguided molecular-targeted compounds. The bioassay-guided isolation addressing cancer cells could be a solution for specifically targeting active compounds and avoiding random screening. Another strategy could be to use a bioinformatics approach and perform in silico studies before in vitro anticancer screening to predict compounds that will interact with the target protein in the cancer cells. From the many well-developed assays, choosing the correct one is key to success in anticancer drug screening. This review summarizes the different in vitro assays used in anticancer drug discovery to aid researchers in selecting those most appropriate.

#### **Conflict of interest statement**

We declare no conflict of interest in this review.

#### Funding

This work was supported by the Internal Research Grant of Sanata Dharma University No. 007/Penel./LPPM-USD/II/2022.

#### Authors' contributions

AS was responsible for the main concept, literature search, manuscript outline, and writing the introduction and future perspective. DSC wrote the *in vitro* cytotoxic assay section. FDES and VKP produced the chemical reactions and cartoons in the figures. DSC, DS, and YSH were responsible for literature search, manuscript preparation, and manuscript editing.

#### References

- Burger AM. Preclinical screening for new anticancer agents. In: Figg WD, McLeon HL (eds.). *Handbook of pharmacokinetics and pharmacodynamics*, *cancer drug discovery and development*. Totowa: Humana Press; 2004, p. 29-45.
- [2] Xu J, Mao W. Overview of research and development for anticancer drugs. J Cancer Ther 2016; 7(10): 762-772.
- [3] Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. *Med Princ Pract* 2016; 25(Suppl 2): 41-59.
- [4] Feng C, Zhou LY, Yu T. New anticancer compound, Oblongifolin C, inhibits tumor growth and promotes apoptosis in HeLa cells through bax activation. *Int J Cancer* 2012; **131**(6): 1445-1454.
- [5] Lu JJ, Bao JL, Chen XP, Huang M, Wang YT. Alkaloids isolated from natural herbs as the anticancer agents. *Evid Based Complement Alternat Med* 2012; 2012: 485042.
- [6] Greco G, Catanzaro E, Fimognari C. Natural products as inducers of noncanonical cell death: A weapon against cancer. *Cancers (Basel)* 2021; 13(2): 304.
- [7] Chamberlin SR, Blucher A, Wu G, Shinto L, Choonoo G, Kulesz-Martin M, et al. Natural product target network reveals potential for cancer combination therapies. *Front Pharmacol* 2019; **10**: 557.
- [8] Eisnhauer EA, Vermorken JB. Principles and process of cancer drug development. J Gynecol Oncol 2000; 5: 344-350.
- [9] Kingston DGI. Modern natural products drug discovery and its relevance to biodiversity conservation. J Nat Prod 2011; 74(3): 496-511.
- [10]Hassan BAR, Yusoff ZBM, Hassali MA, Othman SB. Supportive and palliative care in solid cancer patients. In: Rangel L (ed.). *Cancer treatment–conventional and innovative approaches*. London: IntechOpen; 2013, p. 13.
- [11]Liu K, Liu PC, Liu R, Wu X. Dual AO/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. *Med Sci Monit Basic*

Res 2015; 21: 15-20.

- [12]Day CP, Merlino G, Van Dyke T. Preclinical mouse cancer models: A maze of opportunities and challenges. *Cell* 2015; 163(1): 39-53.
- [13]Kelland L. Preclinical pharmacology and *in vivo* models. In: Huryn DM, Wipf P (eds.). *Natural product chemistry and anticancer drug discovery*. New York: Elsevier; 2008, p. 39-51.
- [14]The United States International Trade Commission. Pharmaceutical products and chemical intermediates, fourth review: Advice concerning the addition of certain products to the pharmaceutical appendix to the HTS. Washington DC, USITC; 2010, p. 148.
- [15]Orlikova B, Legrand N, Panning J, Dicato M, Diederich M. Antiinflammatory and anticancer drugs from nature. *Cancer Treat Res* 2014; 159: 123-143.
- [16]Roy A, McDonald PR, Sittampalam S, Chaguturu R. Open access high throughput drug discovery in the public domain: A Mount Everest in the making. *Curr Pharm Biotechnol* 2010; **11**(7): 764-778.
- [17]Setiawati A. Celecoxib, a COX-2 selective inhibitor, induces cell cycle arrest at the G<sub>2</sub>/M phase in HeLa cervical cancer cells. *Asian Pac J Cancer Prev* 2016; **17**(4): 1655-1660.
- [18]Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: Successes, challenges and opportunities. *Mol Oncol* 2012; 6(2): 155-176.
- [19]Ke X, Shen L. Molecular targeted therapy of cancer: The progress and future prospect. *Front Lab Med* 2017; 1(2): 69-75.
- [20]Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A randomized clinical trial. *JAMA* 2017; 317(1): 37-47.
- [21]Mohamed A, Krajewski K, Cakar B, Ma CX. Targeted therapy for breast cancer. Am J Pathol 2013; 183(4): 1096-1112.
- [22]Adan A, Kiraz Y, Baran Y. Cell proliferation and cytotoxicity assays. *Curr Pharm Biotechnol* 2016; 17(4): 1213-1221.
- [23]Johnson S, Nguyen V, Coder D. Assessment of cell viability. *Curr Protoc Cytom* 2013; 64(1): 1-26.
- [24]Kamiloglu S, Sari G, Ozdal T, Capanoglu E. Guidelines for cell viability assays. *Food Front* 2020; 1(3): 332-349.
- [25]Piccinini F, Tesei A, Arienti C, Bevilacqua A. Cell counting and viability assessment of 2D and 3D cell cultures: Expected reliability of the trypan blue assay. *Biol Proced Online* 2017; 19: 8.
- [26]Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol 2001; 21(1): A3.B.1-A3.B.3.
- [27]Nakayama Y, Tsujinaka T. Acceleration of robust 'biotube' vascular graft fabrication by in-body tissue architecture technology using a novel eosin Y-releasing mold. *J Biomed Mater Res B Appl Biomater* 2014; **102**(2): 231-238.
- [28]Kuo CT, Chen YL, Hsu WT, How SC, Cheng YH, Hsueh SS, et al. Investigating the effects of erythrosine B on amyloid fibril formation derived from lysozyme. *Int J Biol Macromol* 2017; **98**: 159-168.

- [29]Mahto SK, Chandra P, Rhee SW. In vitro models, endpoints and assessment methods for the measurement of cytotoxicity. Toxico Environ Health Sci 2010; 2: 87-93.
- [30]Präbst K, Engelhardt H, Ringgeler S, Hübner H. Basic colorimetric proliferation assays: MTT, WST, and resazurin. *Methods Mol Biol* 2017; 1601: 1-17.
- [31]Tominaga H, Ishiyama M, Ohseto F, Sasamoto K, Hamamoto T, Suzuki K, et al. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. *Anal Commun* 1999; 36(2): 47-50.
- [32]Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: New insights into their cellular reduction. *Biotechnol Annu Rev* 2005; 11: 127-152.
- [33]Riss TL, Moravec RA, Niles Al, Duellman S, Benink HA, Worzella TJ, et al. Cell viability assays. In: Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin CPA, et al. (eds.). Assay guidance manual[Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2021, p. 360-362.
- [34]Kumar P, Nagarajan A, Uchil PD. Analysis of cell viability by the lactate dehydrogenase assay. *Cold Spring Harb Protoc* 2018; 2018(6): 465-468.
- [35]Smith SM, Wunder MB, Norris DA, Shellman YG. A simple protocol for using a LDH-based cytotoxicity assay to assess the effects of death and growth inhibition at the same time. *PLoS One* 2011; 6(11): e26908.
- [36]Ng TY, Ngan HYS, Cheng DKL, Wong LC. Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinumresistant epithelial ovarian cancer using nonsurgical tumor cell samples. *Gynecol Oncol* 2000; **76**(3): 405-408.
- [37]Sumantran VN. Cellular chemosensitivity assays: An overview. *Methods Mol Biol* 2011; 731: 219-236.
- [38]Franken NAP, Rodermond HM, Stap J, Haveman J, Van Bree C. Clonogenic assay of cells *in vitro*. *Nat Protoc* 2006; 1(5): 2315-2319.
- [39]Braselmann H, Michna A, Heß J, Unger K. CFAssay: Statistical analysis of the colony formation assay. *Radiat Oncol* 2015; **10**(223): 1-6.
- [40]Li D, Wang X, Wu JL, Quan WQ, Ma L, Yang F. Tumor-produced versican V1 enhances hCAP18/LL-37 expression in macrophages through activation of TLR2 and vitamin D3 signaling to promote ovarian cancer progression *in vitro*. *PLoS One* 2013; 8(2): e56616.
- [41]Pischel D, Buchbinder JH, Sundmacher K, Lavrik IN, Flassig RJ. A guide to automated apoptosis detection: How to make sense of imaging flow cytometry data. *PLoS One* 2018; **13**(5): e0197208.
- [42]Bi S, Ji B, Zhang Z, Zhang S. A chemiluminescence imaging array for the detection of cancer cells by dual-aptamer recognition and biobar-code nanoprobe-based rolling circle amplification. *Chem Commun* (*Camb*) 2013; 49(33): 3452-3454.
- [43]Szulcek, Bogaard HJ, van Nieuw Amerongen GP. Electric cell-substrate impedance sensing for the quantification of endothelial proliferation, barrier function, and motility. J Vis Exp 2014; 85: 1-12.
- [44]Kramer N, Walzl A, Unger C, Rosner M, Krupitza G, Hengstschläger M, et al. *In vitro* cell migration and invasion assays. *Mutat Res* 2013; **752**(1): 10-24.
- [45]Zhang X, Jang JK. The application of electric cell-substrate impedance sensing (ECIS) biosensor. Int J Biosen Bioelectron 2018; 4(6): 260-261.

- [46]Benson K, Cramer S, Galla HJ. Impedance-based cell monitoring: Barrier properties and beyond. *Fluids Barriers CNS* 2013; 10(1): 5.
- [47]Tran TB, Baek C, Min J. Electric cell-substrate impedance sensing (ECIS) with microelectrode arrays for investigation of cancer cellfibroblasts interaction. *PLoS One* 2016; **11**(4): 1-12.
- [48]Ratri MC, Brilian AI, Setiawati A, Nguyen HT, Soum V, Shin K. Recent advances in regenerative tissue fabrication: Tools, materials, and microenvironment in hierarchical aspects. *Adv Nanobiomed Res* 2021; 1(5): 2000088. doi: 10.1002/anbr.202000088.
- [49]Rahimi-Balaei M, Bergen H, Jiming K, Marzban H. Neural migration during development of the cerebellum. *Front Cell Neurosci* 2018; 12: 484.
- [50]Keller R. Cell migration during gastrulation. Curr Opin Cell Biol 2005; 17(5): 533-541.
- [51]Afewerki T, Ahmed S, Warren D. Emerging regulator of vascular smooth muscle cell migration. J Muscle Res Cell Motil 2019; 40: 185-196.
- [52]Madri JA, Graesser D. Cell migration in the immune system: The evolving inter-related roles of adhesion molecules and proteinases. *Dev Immunol* 2000; 7(2-4): 103-116.
- [53]Nguyen DX, Bos PD, Massagué J. Metastasis: From dissemination to organ-specific colonization. *Nat Rev Cancer* 2009; 9(4): 274-284.
- [54]Welch DR, Hurst DR. Defining the hallmarks of metastasis. *Cancer Res* 2019; **79**(12): 3011-3027.
- [55]Pijuan J, Barceló C, Moreno DF, Maiques O, Sisó P, Marti RM, et al. *In vitro* cell migration, invasion, and adhesion assays: From cell imaging to data analysis. *Front Cell Dev Biol* 2019; 7(107): 1-16.
- [56]Liang CC, Park AY, Guan JL. *In vitro* scratch assay: A convenient and inexpensive method for analysis of cell migration *in vitro*. *Nat Protoc* 2007; 2(2): 329-333.
- [57]Setiawati A, Jang D, Cho D, Cho S, Jeong H, Park S, et al. An accelerated wound-healing surgical suture engineered with an extracellular matrix. *Adv Healthc Mater* 2021; **10**(6): 1-10.
- [58]Kam Y, Guess C, Estrada L, Weidow B, Quaranta V. A novel circular invasion assay mimics *in vivo* invasive behavior of cancer cell lines and distinguishes single-cell motility *in vitro*. *BMC Cancer* 2008; 8(1): 1-12.
- [59]Sekine W, Haraguchi YJ. Thickness limitation and cell viability of multilayered cell sheets and overcoming the diffusion limit by a porousmembrane culture insert. *J Biochips Tiss Chips* 2011; 7(5): 21530777.
- [60]Perrin J, Capitao M, Mougin DM, Guérard F, Faivre CA, Rbah VL, et al. Cell tracking in cancer immunotherapy. *Front Med (Lausanne)* 2020; 7(34): 1-16.
- [61]Bise R, Kanade T, Yin Z, Il HS. Automatic cell tracking applied to analysis of cell migration in wound healing assay. *Proc Annu Int Conf IEEE Eng Med Biol Soc* 2011; 2011: 6174-6179.
- [62]Mencattini A, Di GD, Comes MC, Casti P, Corsi F, Bertani FR, et al. Discovering the hidden messages within cell trajectories using a deep learning approach for *in vitro* evaluation of cancer drug treatments. *Sci Rep* 2020; **10**(1): 1-11.
- [63]Sami DG, Heiba HH, Abdellatif A. Wound healing models: A systematic review of animal and non-animal models. *Wound Med* 2019; 24: 8-17.
- [64]Kenney RM, Loeser A, Whitman NA, Lockett MR. Paper-based Transwell assays: An inexpensive alternative to study cellular invasion.

Analyst 2019; 144: 206-211.

- [65]Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death Differ* 2018; 25(3): 486-541.
- [66]Wong RSY. Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res 2011; 30(1): 1-14.
- [67]Stucchi G, Battevi N, Cairoli S, Consonni D. The prevalence of musculoskeletal disorders in the retail sector: An Italian cross-sectional study on 3380 workers. *Med Lav* 2016; **107**(4): 251-262.
- [68]Banfalvi G. Methods to detect apoptotic cell death. *Apoptosis* 2017; 22(2): 306-323.
- [69]Ribble D, Goldstein NB, Norris DA, Shellman YG. A simple technique for quantifying apoptosis in 96-well plates. *BMC Biotechnol* 2005; 5(1): 1-7.
- [70]Olive PL, Banáth JP. The comet assay: A method to measure DNA damage in individual cells. *Nat Protoc* 2006; 1(1): 23-29.
- [71]Langie SAS, Azqueta A, Collins AR. The comet assay: Past, present, and future. *Front Genet* 2015; 6: 1-3.
- [72]Kyrylkova K, Kyryachenko S, Leid M, Kioussi C. Detection of apoptosis by TUNEL assay. *Methods Mol Biol* 2012; 887: 41-47.
- [73]Mirzayans R, Murray D. Do TUNEL and other apoptosis assays detect cell death in preclinical studies? *Int J Mol Sci* 2020; 21(23): 1-12.
- [74]Garrity MM, Burgart LJ, Riehle DL, Hill EM, Sebo TJ, Witzig T. Identifying and quantifying apoptosis: Navigating technical pitfalls. *Mod Pathol* 2003; 16(4): 389-394.
- [75]Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. *Cardiovasc Res* 2000; 45(3): 528-537.
- [76]Majtnerová P, Roušar T. An overview of apoptosis assays detecting DNA fragmentation. *Mol Biol Rep* 2018; 45(5): 1469-1478.
- [77]Pozarowski P, Grabarek J, Darzynkiewicz Z, Labeling E. Flow cytometry of apoptosis, nucleic acid analysis. *Curr Protoc Cytom* 2003; 21(1): 1-35.
- [78]Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol 2007; 7(7): 532-542.
- [79]Vanden BT, Vanlangenakker N, Parthoens E, Deckers W, Devos M, Festjens N, et al. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. *Cell Death Differ* 2010; **17**(6): 922-930.
- [80]Pietkiewicz S, Schmidt JH, Lavrik IN. Quantification of apoptosis and necroptosis at the single cell level by a combination of imaging flow cytometry with classical Annexin V/propidium iodide staining. J Immunol Methods 2015; 423: 99-103.
- [81]Li M, Tang D, Yang T, Qian D, Xu R. Apoptosis triggering, an important way for natural products from herbal medicines to treat pancreatic cancers. *Front Pharmacol* 2022; **12**: 1-16.
- [82]Kuno T, Tsukamoto T, Hara A, Tanaka T. Cancer chemoprevention through the induction of apoptosis by natural compounds. *J Biophys Chem* 2012; 3(2): 156-173.
- [83]Taylor WF, Moghadam SE, Farimani MM, Ebrahimi MTSN, Jabbarzadeh E. A multi-targeting natural compound with growth inhibitory and anti-

angiogenic properties re-sensitizes chemotherapy resistant cancer. *PLoS One* 2018; **14**(6): e0218125.

- [84]Zintle M, Khwaza V, Blessing AA. Curcumin and its derivatives as potential therapeutic agents in prostate, colon and breast cancers. *Molecules* 2019; 24(23): 4386.
- [85]Park J, Conteas CN. Anti-carcinogenic properties of curcumin on colorectal cancer. World J Gastrointest Oncol 2010; 2(4): 169-176.
- [86]Li L, Hou X, Xu R, Liu C, Tu M. Research review on the pharmacological effects of astragaloside IV. Fundam Clin Pharmacol 2017; 31(1): 17-36.
- [87]Iwanowycz S, Wang J, Hodge J, Wang Y, Yu F, Fan D. Emodin inhibits breast cancer growth by blocking the tumor-promoting feedforward loop between cancer cells and macrophages. *Mol Cancer Ther* 2016; 15(8): 1931-1942.
- [88]Wang Y, Yu H, Zhang J, Ge X, Gao J, Zhang Y, et al. Anti-tumor effect of emodin on gynecological cancer cells. *Cell Oncol (Dordr)* 2015; 38(5): 353-363.
- [89]Ai B, Bie Z, Zhang S, Li A. Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment. Am J Cancer Res 2016; 6(8): 1624-1635.
- [90]Huang M, Lu JJ, Ding J. Natural products in cancer therapy: Past, present and future. *Nat Prod Bioprospect* 2021; 11(1): 5-13.
- [91]Moroz E, Matoori S, Leroux JC. Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts. *Adv Drug Deliv Rev* 2016; 101: 108-121.
- [92]Wu P, Nielsen TE, Clausen MH. Small-molecule kinase inhibitors: An analysis of FDA-approved drugs. *Drug Discov Today* 2016; 21(1): 510.
- [93]Peng Q, Zhang S, Yang Q, Zhang T, Wei XQ, Jiang L, et al. Preformed albumin corona, a protective coating for nanoparticles-based drug delivery system. *Biomaterials* 2013; 34(33): 8521-8530.
- [94]Gao S, Basu S, Yang G, Deb A, Hu M. Oral bioavailability challenges of natural products used in cancer chemoprevention. *Prog Chem* 2013; 25(9): 1553-1574.
- [95]Sarkar FH, Li Y, Wang Z, Padhye S. Lesson learned from nature for the development of novel anti-cancer agents: Implication of isoflavone, curcumin, and their synthetic analogs. *Curr Pharm Des* 2010; 16(16): 1801-1812.
- [96]Khan SA, Chatterton RT, Michel N, Bryk M, Lee O, Ivancic D, et al. Soy isoflavone supplementation for breast cancer risk reduction: A randomized phase [] trial. *Cancer Prev Res* 2012; 5(2): 309-319.
- [97]Pugalendhi P, Manoharan S, Suresh K, Baskaran N. Genistein and daidzein, in combination, protect cellular integrity during 7, 12-dimethylbenz[a]anthracene (DMBA) induced mammary carcinogenesis in Sprague-Dawley rat. Afr J Tradit Complement Altern Med 2011; 8(2): 91-97.
- [98]Cai X, Fang Z, Dou J, Yu A, Zhai G. Bioavailability of quercetin: Problems and promises. *Curr Med Chem* 2013; **20**(20): 2572-2582.
- [99]Song H, Liu B, Dong B, Xu J, Zhou H, Na S, et al. Exosome-based delivery of natural products in cancer therapy. *Front Cell Dev Biol* 2021; 9: 1-10.